Medical Biomimetics Industry Research 2023
June 19, 2023 09:18 ET
|
Research and Markets
Dublin, June 19, 2023 (GLOBE NEWSWIRE) -- The "Medical Biomimetics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" report has been added to ...
Organ Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market Research
June 07, 2023 13:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 07, 2023 (GLOBE NEWSWIRE) -- The global organ transplant rejection medication market is estimated to flourish at a CAGR of 3.9% from 2023 to 2031. According...
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
June 02, 2023 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present...
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
May 11, 2023 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Reported open-label data from ongoing Phase 1b trial of tegoprubart in kidney transplantation demonstrating mean eGFRs from 3 participants above 70 mL/min/1.73m2 at measured timepoints Completed...
Global Organ Transplant Diagnostics Market to 2033: Rise in Incidence of Chronic Diseases Leading to Organ Failure Increases the use of Transplant Diagnostics
May 11, 2023 04:33 ET
|
Research and Markets
Dublin, May 11, 2023 (GLOBE NEWSWIRE) -- The "Organ Transplant Diagnostics Market - A Global and Regional Analysis: Focus on Offering, Application, Technology, Transplant Type, End User, and Country...
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
May 04, 2023 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it plans to release financial results for the first quarter ended March...
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
May 01, 2023 07:00 ET
|
Eledon Pharmaceuticals, Inc.
$35 million in upfront financing with the potential to receive additional aggregate financing up to $105 million, subject to achieving clinical development milestones, plus up to $45 million upon...
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
March 31, 2023 06:00 ET
|
Eledon Pharmaceuticals, Inc.
Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days Strong graft function observed in all three participants with mean eGFRs above 70...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
March 30, 2023 16:01 ET
|
Eledon Pharmaceuticals, Inc.
`Four patients enrolled in open-label Phase 1b kidney transplant trial with clinical data on first three patients to be presented at the World Congress of Nephrology (WCN) on March 31, 2023 Safety...
2022 Solid Organ Transplantation Technologies Report: eHealth Services and Transplant Management Solutions Present Opportunities
March 28, 2023 10:48 ET
|
Research and Markets
Dublin, March 28, 2023 (GLOBE NEWSWIRE) -- The "Solid Organ Transplantation Technologies and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The study covers...